XW04306 - Introduction Central Vein to New Technology Group 6 with Brexanolone, Percutaneous Approach
XW04308 - Introduction Central Vein to New Technology Group 8 with Spesolimab Monoclonal Antibody, Percutaneous Approach
XW0432
XW04326 - Introduction Central Vein to New Technology Group 6 with Nerinitide, Percutaneous Approach
XW0433
XW04336 - Introduction Central Vein to New Technology Group 6 with Durvalumab Antineoplastic, Percutaneous Approach
XW0433A - Introduction Central Vein to New Technology Group 10 with Bentracimab, Ticagrelor Reversal Agent, Percutaneous Approach
XW0434
XW0434A - Introduction Central Vein to New Technology Group 10 with Cefepime-taniborbactam Anti-infective, Percutaneous Approach
XW0435
XW04357 - Introduction Central Vein to New Technology Group 7 with Narsoplimab Monoclonal Antibody, Percutaneous Approach
XW04358 - Introduction Central Vein to New Technology Group 8 with Mosunetuzumab Antineoplastic, Percutaneous Approach
XW0435A - Introduction Central Vein to New Technology Group 10 with Ceftobiprole Medocaril Anti-infective, Percutaneous Approach
XW0436
XW04366 - Introduction Central Vein to New Technology Group 6 with Lefamulin Anti-infective, Percutaneous Approach
XW04367 - Introduction Central Vein to New Technology Group 7 with Terlipressin, Percutaneous Approach
XW04368 - Introduction Central Vein to New Technology Group 8 with Afamitresgene Autoleucel Immunotherapy, Percutaneous Approach
XW0437
XW04372 - Introduction Central Vein to New Technology Group 2 with Coagulation Factor Xa, Inactivated, Percutaneous Approach
XW04377 - Introduction Central Vein to New Technology Group 7 with Trilaciclib, Percutaneous Approach
XW04378 - Introduction Central Vein to New Technology Group 8 with Tabelecleucel Immunotherapy, Percutaneous Approach
XW0438
XW04387 - Introduction Central Vein to New Technology Group 7 with Lurbinectedin, Percutaneous Approach
XW04388 - Introduction Central Vein to New Technology Group 8 with Treosulfan, Percutaneous Approach
XW0438A - Introduction Central Vein to New Technology Group 10 with Obecabtagene Autoleucel, Percutaneous Approach
XW0439
XW04396 - Introduction Central Vein to New Technology Group 6 with Ceftolozane/Tazobactam Anti-infective, Percutaneous Approach
XW04398 - Introduction Central Vein to New Technology Group 8 with Inebilizumab-cdon, Percutaneous Approach
XW0439A - Introduction Central Vein to New Technology Group 10 with Odronextamab Antineoplastic, Percutaneous Approach
XW043A
XW043A6 - Introduction Central Vein to New Technology Group 6 with Cefiderocol Anti-infective, Percutaneous Approach
XW043A7 - Introduction Central Vein to New Technology Group 7 with Ciltacabtagene Autoleucel, Percutaneous Approach
XW043B
XW043B3 - Introduction Central Vein to New Technology Group 3 with Cytarabine and Daunorubicin Liposome Antineoplastic, Percutaneous Approach
XW043B6 - Introduction Central Vein to New Technology Group 6 with Omadacycline Anti-infective, Percutaneous Approach
XW043B7 - Introduction Central Vein to New Technology Group 7 with Amivantamab Monoclonal Antibody, Percutaneous Approach
XW043BA - Introduction Central Vein to New Technology Group 10 with Orca-T Allogeneic T-cell Immunotherapy, Percutaneous Approach
XW043C
XW043C6 - Introduction Central Vein to New Technology Group 6 with Eculizumab, Percutaneous Approach
XW043C7 - Introduction Central Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous, Percutaneous Approach
XW043CA - Introduction Central Vein to New Technology Group 10 with Zanidatamab Antineoplastic, Percutaneous Approach
XW043D
XW043D6 - Introduction Central Vein to New Technology Group 6 with Atezolizumab Antineoplastic, Percutaneous Approach
XW043E
XW043E5 - Introduction Central Vein to New Technology Group 5 with Remdesivir Anti-infective, Percutaneous Approach
XW043E6 - Introduction Central Vein to New Technology Group 6 with Etesevimab Monoclonal Antibody, Percutaneous Approach
XW043F
XW043F3 - Introduction Central Vein to New Technology Group 3 with Other New Technology Therapeutic Substance, Percutaneous Approach
XW043F5 - Introduction Central Vein to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach
XW043F6 - Introduction Central Vein to New Technology Group 6 with Bamlanivimab Monoclonal Antibody, Percutaneous Approach
XW043FA - Introduction Central Vein to New Technology Group 10 with Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy, Percutaneous Approach
XW043G
XW043G5 - Introduction Central Vein to New Technology Group 5 with Sarilumab, Percutaneous Approach
XW043G6 - Introduction Central Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
XW043G7 - Introduction Central Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic, Percutaneous Approach
XW043H
XW043H5 - Introduction Central Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach
XW043H6 - Introduction Central Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
XW043H7 - Introduction Central Vein to New Technology Group 7 with Axicabtagene Ciloleucel Immunotherapy, Percutaneous Approach
XW043J
XW043J7 - Introduction Central Vein to New Technology Group 7 with Tisagenlecleucel Immunotherapy, Percutaneous Approach
XW043K
XW043K7 - Introduction Central Vein to New Technology Group 7 with Idecabtagene Vicleucel Immunotherapy, Percutaneous Approach
XW043K9 - Introduction Central Vein to New Technology Group 9 with Sulbactam-Durlobactam, Percutaneous Approach
XW043L
XW043L6 - Introduction Central Vein to New Technology Group 6 with CD24Fc Immunomodulator, Percutaneous Approach
XW043L7 - Introduction Central Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach
XW043M
XW043M7 - Introduction Central Vein to New Technology Group 7 with Brexucabtagene Autoleucel Immunotherapy, Percutaneous Approach
XW043N
XW043N7 - Introduction Central Vein to New Technology Group 7 with Lisocabtagene Maraleucel Immunotherapy, Percutaneous Approach
XW043P
XW043P9 - Introduction Central Vein to New Technology Group 9 with Glofitamab Antineoplastic, Percutaneous Approach
XW043Q
XW043Q5 - Introduction Central Vein to New Technology Group 5 with Tagraxofusp-erzs Antineoplastic, Percutaneous Approach
XW043Q9 - Introduction Central Vein to New Technology Group 9 with Posoleucel, Percutaneous Approach
XW043R
XW043R9 - Introduction Central Vein to New Technology Group 9 with Rezafungin, Percutaneous Approach
XW043S
XW043S5 - Introduction Central Vein to New Technology Group 5 with Iobenguane I-131 Antineoplastic, Percutaneous Approach
XW043W
XW043W5 - Introduction Central Vein to New Technology Group 5 with Caplacizumab, Percutaneous Approach
